HERPESVIRUS VACCINES

Adler, 1996, Current prospects for immunization against cytomegalovirus disease, Infectious Agents and Disease, 5, 29 Adler, 1995, Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age, J Infect Dis, 171, 26, 10.1093/infdis/171.1.26 Anderson, 1950, An attempt to vaccinate against herpes simplex, Aust J Exp Biol Med Sci, 28, 579, 10.1038/icb.1950.58 Arbeter, 1986, Varicella vaccine studies in healthy children and adults, Pediatrics, 78, 748 Asano, 1996, Varicella vaccine: The Japanese experience, J Infect Dis, 174, S310, 10.1093/infdis/174.Supplement_3.S310 Asano, 1987, Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination, Biken J, 25, 43 Asano, 1985, Viremia is present in incubation period in nonimmunocompromised children with varicella, J Pediatr, 106, 69, 10.1016/S0022-3476(85)80468-6 Asano, 1994, Experience and reason: Twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine, Pediatrics, 94, 524 Asano, 1993, Postexposure prophylaxis of varicella in family contacts by oral acyclovir, Pediatrics, 92, 219 Balfour, 1985, Cytomegalovirus vaccine trial in 400 renal transplant candidates, Transplant Proc, 17, 81 Barnes, 1995, Peptide-based EBV vaccine in phase I trial, Pharma Weekly, 1, 11, 10.2165/00128413-199509850-00025 Bernstein, 1993, Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine, Pediatrics, 92, 833 Bourne, 1996, DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2, Vaccine, 14, 1230, 10.1016/S0264-410X(96)00027-8 Boursnell, 1997, A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease, J Infect Dis, 175, 16, 10.1093/infdis/175.1.16 Britt, 1988, Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB), J Virol, 62, 3309, 10.1128/JVI.62.9.3309-3318.1988 Brunell, 1987, Varicella-like illness caused by live varicella vaccine in children with acute lymphocytic leukemia, Pediatrics, 79, 922 Brunell, 1981, Risk herpes zoster in children with leukemia: Varicella vaccine compared with history of chickenpox, Pediatrics, 77, 53 Cadoz M, Micoud M, Seigneurin JM: Phase I trial of R7020: A live-attenuated recombinant herpes simplex virus (HSV) candidate vaccine. Presented at The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992 Centers for Disease Control and Preventions, 1996, Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, 45, 1 Cha, 1996, Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains, J Virol, 70, 78, 10.1128/JVI.70.1.78-83.1996 Cohen, 1998, Infection of cells with varicella-zoster virus down-regulates surface expression of class I major histocompatibility complex antigens, J Infect Dis, 177, 1390, 10.1086/517821 Committee on Infectious Diseases of the American Academy of Pediatrics, 1995, Recommendations for the use of live attenuated varicella vaccine, Pediatrics, 95, 791 Corey, 1986, Infections with herpes simplex viruses, N Engl J Med, 314, 686, 10.1056/NEJM198603133141105 Dargan, 1997, The effect of herpes simplex virus type 1 L-particles on virus entry, replication, and the infectivity of naked herpesvirus DNA, Virology, 239, 378, 10.1006/viro.1997.8893 De Moragas, 1957, The outcome of patients with herpes zoster, Arch Dermatol, 75, 193, 10.1001/archderm.1957.01550140037006 Fleming, 1997, Herpes simplex virus type 2 in the United States, 1976 to 1994, N Engl J Med, 337, 1105, 10.1056/NEJM199710163371601 Ford-Jones, 1996, Cytomegalovirus infections in Toronto child-care centers: A prospective study of viral excretion in children and seroconversion among day-care providers, Pediatr Infect Dis J, 15, 507, 10.1097/00006454-199606000-00007 Fowler, 1992, The outcome of congenital cytomegalovirus infection in relation to maternal antibody status, N Engl J Med, 326, 663, 10.1056/NEJM199203053261003 Gallichan, 1998, Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization, J Infect Dis, 177, 1155, 10.1086/515286 Gershon, 1996, The protective effect of immunologic boosting against zoster: An analysis in leukemic children who were vaccinated against chickenpox, J Infect Dis, 173, 450, 10.1093/infdis/173.2.450 Gershon, 1997, Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection, J Infect Dis, 176, 1496, 10.1086/514147 Gilden, 1992, Varicella-zoster virus reactivation without rash, J Infect Dis, 166, S30, 10.1093/infdis/166.Supplement_1.S30 Gonczol, 1995, Preclinical evaluation of an ALVAC (canarypox)—human cytomegalovirus glycoprotein B vaccine candidate, Vaccine, 13, 1080, 10.1016/0264-410X(95)00048-6 Gu, 1995, First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen, Dev Biol Stand, 84, 171 Halloran, 1994, Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children, Am J Epidemiol, 140, 81, 10.1093/oxfordjournals.aje.a117238 Hardy, 1991, The incidence of zoster after immunization with live attenuated varicella vaccine, N Engl J Med, 325, 1545, 10.1056/NEJM199111283252204 Hope-Simpson, 1965, The nature of herpes zoster: A long-term study and a new hypothesis, Proc R Soc Lond B Biol Sci, 58, 9 Johnson, 1990, A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States, N Engl J Med, 321, 7, 10.1056/NEJM198907063210102 Katsushima, 1982, Application of a live varicella vaccine to hospitalized children and its follow-up study, Biken J, 25, 29 Kemble G, Duke G, Winter R, Spaete R: A new generation of live, attenuated cytomegalovirus (CMV) vaccine strains. Presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996 Kern, 1964, Vaccine therapy in recurrent herpes simplex, Dermatology, 89, 944 Khanna, 1995, Immune regulation in Epstein-Barr virus-associated diseases, Microbiol Rev, 59, 387, 10.1128/MMBR.59.3.387-405.1995 Kost, 1996, Postherpetic neuralgia—pathogenesis, treatment, and prevention, N Engl J Med, 335, 32, 10.1056/NEJM199607043350107 Krause, 1995, Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine, J Pediatr, 127, 518, 10.1016/S0022-3476(95)70106-0 Kriesel, 1996, Nucleic acid vaccine encoding gD2 protects mice from herpes simplex virus type 2 disease, J Infect Dis, 173, 536, 10.1093/infdis/173.3.536 LaRussa, 1996, Varicella vaccine for immunocompromised children: Results of collaborative studies in the United States and Canada, J Infect Dis, 174, S320, 10.1093/infdis/174.Supplement_3.S320 Lawrence, 1988, The risk of zoster after varicella vaccination in children with leukemia, N Engl J Med, 318, 543, 10.1056/NEJM198803033180904 Leroux-Roels G, Moreau E, Desombere I, et al: Safety, humoral and cellular immune responses of three different doses of glycoprotein D(gD2t) in herpes simplex vaccine with aluminum and MPL. Presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1997 Levin, 1996, The varicella vaccine: Prevention of herpes zoster, Infect Dis Clin North Am, 10, 657, 10.1016/S0891-5520(05)70319-6 Lieu, 1994, Cost-effectiveness of a routine varicella vaccination program for U.S. children, JAMA, 271, 375, 10.1001/jama.271.5.375 Ljungman, 1986, Clinical and subclinical reactivation of varicella-zoster virus in immunocompromised patients, J Infect Dis, 153, 840, 10.1093/infdis/153.5.840 Malinoski FJ, Linden J, Smith J, et al: Immunization of plasmapharesis donors with cytomegalovirus vaccine composed of gB glycoprotein and MF-59 adjuvant. Presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997 Manickan, 1995, Genetic immunization against herpes simplex virus: Protection is mediated by CD4+ T lymphocytes, J Immunol, 155, 259 Marshall GS, Frey S, Pass R, et al: Safety and immunogenicity of CMV gBMF59 vaccine in healthy seronegative adults. Presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997 Meignier, 1990, In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotu trivargatus), J Infect Dis, 162, 313, 10.1093/infdis/162.2.313 Merck & Co, 1998, Varivax (Varicella Virus Vaccine Live [Oka/Merck]) package circular, 1762 Mertz, 1990, Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection, J Infect Dis, 161, 653, 10.1093/infdis/161.4.653 Miller, 1998, Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway, J Exp Med, 187, 675, 10.1084/jem.187.5.675 Morgan, 1992, Epstein-Barr virus vaccines, Vaccine, 10, 563, 10.1016/0264-410X(92)90434-L Pass, 1995, Immunogenicity of a recombinant CMV gB Vaccine, Pediatr Res, 37, 185A Ploegh, 1998, Viral strategies of immune evasion, Science, 280, 248, 10.1126/science.280.5361.248 Plotkin, 1976, Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus, J Infect Dis, 134, 470, 10.1093/infdis/134.5.470 Plotkin, 1994, Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients, Transplantation, 58, 1176, 10.1097/00007890-199412270-00006 Porath, 1990, Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease, Rev Infect Dis, 12, 31, 10.1093/clinids/12.1.31 Ragozzino, 1982, Population-based study of herpes zoster and its sequelae, Medicine (Baltimore), 61, 310, 10.1097/00005792-198209000-00003 Rooney, 1986, Acquisition of genital herpes from an asymptomatic sexual partner, N Engl J Med, 314, 1561, 10.1056/NEJM198606123142407 Ross, 1962, Modification of chickenpox in family contacts by administration of gamma-globulin, N Engl J Med, 267, 369, 10.1056/NEJM196208232670801 Snydman, 1987, Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients, N Engl J Med, 317, 1049, 10.1056/NEJM198710223171703 Spector, 1998, Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs, J Infect Dis, 177, 143, 10.1086/515278 Spingarn, 1998, Universal vaccination against varicella, N Engl J Med, 338, 683, 10.1056/NEJM199803053381011 Stagno, 1982, Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection, N Engl J Med, 306, 945, 10.1056/NEJM198204223061601 Stamm, 1988, The association between genital ulcer disease and acquisition of HIV infection in homosexual men, JAMA, 260, 1429, 10.1001/jama.260.10.1429 Straus, 1994, Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes, Lancet, 343, 1460, 10.1016/S0140-6736(94)92581-X Straus, 1988, NIH conference. Varicella-zoster virus infections: Biology, natural history, treatment, and prevention, Ann Intern Med, 108, 221, 10.7326/0003-4819-108-2-221 Straus, 1993, Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine, J Infect Dis, 167, 1045, 10.1093/infdis/167.5.1045 Straus, 1997, Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial, J Infect Dis, 176, 1129, 10.1086/514103 Takahashi, 1986, Clinical overview of varicella vaccine: Development and early studies, Pediatrics, 78, 736 Takahashi, 1974, Live vaccine used to prevent the spread of varicella in children in hospital, Lancet, 2, 1288, 10.1016/S0140-6736(74)90144-5 Thorley-Lawson, 1980, Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity, Proc Natl Acad Sci U S A, 77, 5307, 10.1073/pnas.77.9.5307 Varis, 1996, Efficacy of high-titer live attenuated varicella vaccine in healthy young children, J Infect Dis, 174, S330, 10.1093/infdis/174.Supplement_3.S330 Vugia, 1996, Invasive group A streptococcal infections in children with varicella in southern California, Pediatr Infect Dis J, 15, 146, 10.1097/00006454-199602000-00011 Wald, 1995, Virologic characteristics of subclinical and symptomatic genital herpes infections, N Engl J Med, 333, 770, 10.1056/NEJM199509213331205 Wasmuth, 1990, Sensitive ELISA for antibody to varicella-zoster virus using purified VZV glycoprotein antigen, J Med Virol, 32, 189, 10.1002/jmv.1890320310 Weibel, 1984, Live attenuated varicella vaccine: Efficacy trial in healthy children, N Engl J Med, 310, 1409, 10.1056/NEJM198405313102201 Wharton, 1996, The epidemiology of varicella-zoster virus infections, Infect Dis Clin North Am, 10, 571, 10.1016/S0891-5520(05)70313-5 White, 1992, Modified cases of chickenpox after varicella vaccination: Correlation of protection with antibody response, Pediatr Infect Dis J, 11, 19, 10.1097/00006454-199201000-00006 Whiteley, 1993, Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models, J Clin Invest, 91, 2837, 10.1172/JCI116527 Wilson, 1992, Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation, J Infect Dis, 165, 119, 10.1093/infdis/165.1.119